Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer

SIMPLE SUMMARY: Breast cancer is the most common cancer among women worldwide. Overexpression of the HER2 receptor is associated with a worse prognosis and poorer survival. Consequently, several anti-HER2 therapies have been developed, such as trastuzumab. However, resistance still affects a signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Guijarro, Ana Carla, Sanchez, Angel Matias, Flamini, Marina Inés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486824/
https://www.ncbi.nlm.nih.gov/pubmed/37686651
http://dx.doi.org/10.3390/cancers15174374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486824/
https://www.ncbi.nlm.nih.gov/pubmed/37686651
http://dx.doi.org/10.3390/cancers15174374

Ejemplares similares